Title:
HTLV-I-SPECIFIC CTL ACTIVATOR
Document Type and Number:
WIPO Patent Application WO/2020/246535
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing an HTLV-I-specific CTL activator, and a method for producing the same. In the present invention, peripheral blood mononuclear cells harvested from a subject infected with human T cell leukemia virus type I (HTLV-1) are cultured in a medium for animal cell culture, and the peripheral blood mononuclear cells obtained thereby are treated with an anti-cancer agent. The peripheral blood mononuclear cells thus obtained are used as an HTLV-I-specific CTL activator.
Inventors:
KANNAGI MARI (JP)
HASEGAWA ATSUHIKO (JP)
HASEGAWA ATSUHIKO (JP)
Application Number:
PCT/JP2020/022065
Publication Date:
December 10, 2020
Filing Date:
June 04, 2020
Export Citation:
Assignee:
UNIV NAT CORP TOKYO MEDICAL & DENTAL (JP)
International Classes:
A61K35/14; A61P35/02; A61P37/04; C12N5/078
Domestic Patent References:
| WO2006035681A1 | 2006-04-06 | |||
| WO2004092373A1 | 2004-10-28 |
Foreign References:
| JP2016077185A | 2016-05-16 | |||
| JP2012090574A | 2012-05-17 |
Attorney, Agent or Firm:
HIROTA, Masanori (JP)
Download PDF:
Previous Patent: DRUG AUDIT SUPPORT DEVICE, DRUG AUDIT SUPPORT SYSTEM, AND DRUG AUDIT METHOD
Next Patent: STRETCHABLE FILM
Next Patent: STRETCHABLE FILM